MOLN Stock Analysis: Buy, Sell, or Hold?
MOLN - Molecular Partners AG American Depositary Shares
$3.81
-0.14 (-3.54%)
▼
5d:
-1.04%
30d:
+0.26%
90d:
-18.76%
BUY
HIGH Confidence
Analysis Updated: Jun 22, 2026 12:00 AM ET
Earnings: Jun 03, 2026
0d
Get Alerted When MOLN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: MOLN shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: MOLN shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: MOLN is currently trading at $3.81, which is considered slightly low relative to its 30-day fair value range of $3.79 to $4.06. From a valuation perspective, the stock is trading at a discount (Forward PE: -18.3) compared to its historical average (31.9). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, MOLN is in a downtrend. Immediate support is located at $3.67, while resistance sits at $4.20. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: MOLN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $10.81 (+173.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, MOLN is in a downtrend. Immediate support is located at $3.67, while resistance sits at $4.20. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: MOLN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $10.81 (+173.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$3.79 -
$4.06
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
90.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.5%)
- BULLISH: Trading 173.8% below Wall St target ($10.81)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$3.79 -
$4.06
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$3.67
Resistance Level
$4.20
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-18.29
Wall Street Target
$10.81
(+173.8%)
Revenue Growth (YoY)
-100.0%
PE vs Historical
-18.3 vs 31.9
CHEAP
Share & Embed Analysis
Last updated: June 23, 2026 1:13 PM ET
Data refreshes hourly during market hours. Next update: 2:13 PM
Data refreshes hourly during market hours. Next update: 2:13 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MOLN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 65 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 58 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 60 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$83 | 61 BUY |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 69 BUY |
